Related Experiment Videos
[Organ specific MRI contrast media in general practice]
1Universitätsklinik für Radiodiagnostik, Währinger Gürtel 18-20, A-1090 Wien. wolfgang.schima@univie.ac.at
Wiener Medizinische Wochenschrift. Supplement
|March 8, 2003
Summary
Organ-specific MRI contrast agents enhance cancer detection and staging. Liver-specific agents outperform CT for liver metastases, while new agents show promise for pancreatic and lymph node imaging.
Area of Science:
- Radiology
- Medical Imaging
- Oncology
Background:
- Conventional MRI uses non-specific contrast agents for malignancy detection.
- Advancements in organ-specific contrast agents are expanding MRI's role in body imaging.
Purpose of the Study:
- To review the clinical applications of newly developed organ-specific MRI contrast agents.
- To compare the efficacy of these agents with conventional methods like CT.
Main Methods:
- Review of studies utilizing liver-specific (hepatobiliary, reticuloendothelial), pancreatic, blood-pool, and lymph node-targeting MRI contrast agents.
- Comparison of MRI findings with helical CT and spiral CT in detecting and staging various cancers.
Main Results:
- Liver-specific MRI is superior to CT for detecting liver metastases.
- Mangafodipir-enhanced MRI is comparable or superior to CT for pancreatic cancer staging and detection.
- Ultrasmall iron oxide particles (USPIO) improve lymph node staging accuracy for head-neck, lung, and pelvic cancers.
Conclusions:
- Organ-specific MRI contrast agents offer diverse clinical applications in oncology.
- Further research will clarify the comparative role of contrast-enhanced MRI versus multi-detector array CT.